<DOC>
	<DOCNO>NCT00234741</DOCNO>
	<brief_summary>STA-5326 oral experimental drug show block release interleukin-12 peripheral blood mononuclear cell . Given activity immune system , STA-5326 mesylate potential treatment various autoimmune disease , Crohn 's disease , mediate inappropriate expression Th1 cytokine . This study evaluate use STA-5326 mesylate patient moderate severe , active Crohn 's disease . Study visit include screen visit , 4 treatment period visit 4 week follow-up visit occur 7 day follow end treatment . Subjects may continue treatment additional 4 week open label STA-5326 mesylate administration include additional 2 treatment period visit . Subjects undergo colonoscopy biopsy collection baseline , end 4 week blind phase end 4 week open label phase .</brief_summary>
	<brief_title>Study STA-5326 Mesylate Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Is male female age 18 75 year . Has Crohn 's disease diagnose definitively prior Screening ( base upon clinical , endoscopic , radiologic imaging , histological assessment ) . Has CDAI score 220 450 , inclusive Baseline . Has clinically significant disease ( eg , renal , hepatic , neurological , cardiovascular , pulmonary , endocrinologic , psychiatric , hematologic , urologic , acute chronic illness ) opinion investigator would make subject unsuitable candidate study . Is woman positive pregnancy test , breastfeeding , sexually active without use birth control course study Followup period . Is woman childbearing potential man agree use 2 form contraception course study Followup period . Has clinically significant hematologic , hepatic renal laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>